Incidence and Risk Factors of Recurrent Anterior Uveitis in Initial Acute-Onset Vogt-Koyanagi-Harada Disease
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: We report the estimated incidence of, and risk factors for, recurrent anterior uveitis in patients with initial acute-onset Vogt-Koyanagi-Harada (VKH) disease using survival analyses. Methods: Patients who were diagnosed with initial acute-onset VKH disease during 2003–2022 at two university hospitals were included. Recurrent anterior uveitis was defined as the first occurrence of the granulomatous anterior uveitis with anterior chamber cells and flare of 2+ or more by the Standardization of Uveitis Nomenclature (SUN) Working Group grading scheme, after the disappearance of conspicuous uveitis and serous retinal detachment for at least 3 months, regardless of systemic or local treatment. The univariate log-rank test and multivariate Cox regression analyses were performed, including patients’ demographic characteristics, underlying diseases, presence of prodromal symptoms, duration of visual symptoms, visual acuity, slit-lamp and fundus findings, and height of serous retinal detachment. The treatment method and response to treatment were also included. Results: The estimated incidence was 39.3% at 10 years. Fifteen of 55 patients (27.3%) had recurrent anterior uveitis during the mean follow-up of 4.5 years. The presence of focal posterior synechiae at the diagnosis increased the risk of recurrent anterior uveitis 6.97-fold compared to the absence of synechiae (95% confidence interval [CI], 2.20–22.11; p < 0.001). Use of systemic high-dose steroid therapy more than 7 days after the development of visual symptoms resulted in a hazard ratio of 4.55 (95% CI, 1.27–16.40; p = 0.020). Conclusions: This study reports the estimated incidence and risk factors of recurrent anterior uveitis in VKH disease from survival analyses. However, because of the retrospective nature of this study, it is hard to confirm the consistency of the medical records regarding risk factors, thus, the presence of focal posterior synechiae can be inconclusive as a risk factor. Further studies are warranted.
Abstract
Purpose: We report the estimated incidence of, and risk factors for, recurrent anterior uveitis in patients with initial acute-onset Vogt-Koyanagi-Harada (VKH) disease using survival analyses. Methods: Patients who were diagnosed with initial acute-onset VKH disease during 2003–2022 at two university hospitals were included. Recurrent anterior uveitis was defined as the first occurrence of the granulomatous anterior uveitis with anterior chamber cells and flare of 2+ or more by the Standardization of Uveitis Nomenclature (SUN) Working Group grading scheme, after the disappearance of conspicuous uveitis and serous retinal detachment for at least 3 months, regardless of systemic or local treatment. The univariate log-rank test and multivariate Cox regression analyses were performed, including patients’ demographic characteristics, underlying diseases, presence of prodromal symptoms, duration of visual symptoms, visual acuity, slit-lamp and fundus findings, and height of serous retinal detachment. The treatment method and response to treatment were also included. Results: The estimated incidence was 39.3% at 10 years. Fifteen of 55 patients (27.3%) had recurrent anterior uveitis during the mean follow-up of 4.5 years. The presence of focal posterior synechiae at the diagnosis increased the risk of recurrent anterior uveitis 6.97-fold compared to the absence of synechiae (95% confidence interval [CI], 2.20–22.11; p < 0.001). Use of systemic high-dose steroid therapy more than 7 days after the development of visual symptoms resulted in a hazard ratio of 4.55 (95% CI, 1.27–16.40; p = 0.020). Conclusions: This study reports the estimated incidence and risk factors of recurrent anterior uveitis in VKH disease from survival analyses. However, because of the retrospective nature of this study, it is hard to confirm the consistency of the medical records regarding risk factors, thus, the presence of focal posterior synechiae can be inconclusive as a risk factor. Further studies are warranted.
참고문헌 (29)
- Yamaki K, "Tyrosinase family proteins are antigens specific to Vogt-Koyanagi-Harada disease", J Immunol, 165, pp.7323~7329 (2000)
- Jabs DA, "Improving the diagnostic criteria for Vogt-Koyanagi-Harada disease", JAMA Ophthalmol, 136, pp.1032~1033 (2018)
- Nakayama M, "Clinical features and visual outcomes of 111 patients with new-onset acute Vogt-Koyanagi-Harada disease treated with pulse intravenous corticosteroids", Br J Ophthalmol, 103, pp.274~278 (2019)
- Herbort CP Jr, "Vogt-Koyanagi-Harada disease : recurrence rates after initial-onset disease differ according to treatment modality and geographic area", Int Ophthalmol, 40, pp.2423~2433 (2020)
- Abu El-Asrar AM, "Prognostic factors for clinical outcomes in patients with Vogt-Koyanagi-Harada disease treated with high-dose corticosteroids", Acta Ophthalmol, 91, pp.e486~93 (2013)
- Alvarez-Guzman C, "Risk factors for secondary Glaucoma in patients with Vogt-Koyanagi-Harada disease", J Ophthalmic Inflamm Infect, 12, pp.22~ (2022)
- Alvarez-Guzman C, "High prevalence of angle-closure glaucoma in Vogt-Koyanagi-Harada disease", Int Ophthalmol, 42, pp.3913~3921 (2022)
- AlBloushi A F, "Incidence, risk factors and surgical outcomes of cataract among patients with Vogt-Koyanagi-Harada disease", Ocul Immunol Inflamm, 29, pp.128~136 (2021)
- Jabs DA, "Standardization of uveitis nomenclature for reporting clinical data. Results of the First International Workshop", Am J Ophthalmol, 140, pp.509~516 (2005)
- Maruyama K, "Predictors of recurrence in Vogt-Koyanagi-Harada disease", Ophthalmol Retina, 2, pp.343~350 (2018)
- Chee SP, "Role of optical coherence tomography in the prognosis of Vogt-Koyanagi-Harada disease", Ocul Immunol Inflamm, 29, pp.118~123 (2021)
- Chee SP, "The prognostic value of angiography in Vogt-Koyanagi-Harada disease", Am J Ophthalmol, 150, pp.888~893 (2010)
- Taylor S, "Recurrent anterior uveitis in patients with Vogt-Koyanagi-Harada syndrome", Arch Ophthalmol, 122, pp.922~923 (2004)
- Urzua CA, "Initial-onset acute and chronic recurrent stages are two distinctive courses of Vogt-Koyanagi-Harada disease", J Ophthalmic Inflamm Infect, 10, pp.23~ (2020)
- 김지수, "스테로이드 감량 치료 중 재발을 보인 보크트-고야나기-하라다증후군의 임상양상", 대한안과학회지, 60(4), pp.331~339 (2019), 대한안과학회
- Murakami S, "A nationwide survey on the occurrence of Vogt-Koyanagi-Harada disease in Japan", Jpn J Ophthalmol, 38, pp.208~213 (1994)
- Abu El-Asrar AM, "New perspectives on the immunopathogenesis and treatment of uveitis associated with Vogt-Koyanagi-Harada disease", Front Med(Lausanne), 8, pp.705796~ (2021)
- Seong MC, "Association of HLA with Vogt-Koyanagi-Harada disease in Korean", J Korean Ophthalmol Soc, 40, pp.3057~3064 (1999)
- Tagawa Y, "Choroidal thickening prior to anterior recurrence in patients with Vogt-Koyanagi-Harada disease", Br J Ophthalmol, 100, pp.473~477 (2016)
- Ormaechea MS, "Correlation between subfoveal choroidal thickness and anterior segment inf lammation in patients with chronic stage of Vogt-Koyanagi-Harada disease", Ocul Immunol Inf lamm, 30, pp.646~651 (2022)
- Silpa-Archa S, "Analysis of three-dimensional choroidal volume with enhanced depth imaging f indings in patients with recur rent Vogt-Koyanagi-Harada disease", Curr Eye Res, 46, pp.1010~1017 (2021)
- Liu S, "The choroidal vascularity index decreases and choroidal thickness increases in Vogt-Koyanagi-Harada disease patients during a recurrent anterior uveitis attack", Ocul Immunol Inflamm, 26, pp.1237~1243 (2018)
- Baltmr A, "Vogt-Koyanagi-Harada syndrome : current perspectives", Clin Ophthalmol, 10, pp.2345~2361 (2016)
- Lavezzo MM, "Vogt-Koyanagi-Harada disease : review of a rare autoimmune disease targeting antigens of melanocytes", Orphanet J Rare Dis, 11, pp.29~ (2016)
- Agarwal M, "Triple agent immunosuppressive therapy in Vogt-Koyanagi-Harada syndrome", Ocul Immunol Inflamm, 14, pp.333~339 (2006)
- Papasavvas I, "Vogt-Koyanagi-Harada is a curable autoimmune disease : early diagnosis and immediate dual steroidal and non-steroidal immunosuppression are crucial prerequisites", J Curr Ophthalmol, 32, pp.310~314 (2020)
- Abu El-Asrar AM, "Mycophenolate mofetil combined with systemic corticosteroids prevents progression to chronic recurrent inflammation and development of ‘su nset glow f u ndus’ in initial-onset acute uveitis associated with Vogt-Koyanagi-Harada disease", Acta Ophthalmol, 95, pp.85~90 (2017)
- Ono T, "Comparison of combination therapy of prednisolone and cyclosporine with corticosteroid pulse therapy in Vogt-Koyanagi-Harada disease", Jpn J Ophthalmol, 66, pp.119~129 (2022)
- Byon IS, "Intravitreal triamcinolone acetonide for rebound phenomenon after high-dose intravenous steroid treatment in Vogt-Koyanagi-Harada disease", Clin Ophthalmol, 5, pp.1589~1591 (2011)